Business
Cantor Fitzgerald Healthcare Conference 2017
Cantor Fitzgerald Healthcare Conference 2017.
About this update from Oxford Biomedica Plc
[{"type":"text","content":"\n \nRNS Number : 6933R Oxford Biomedica PLC 25 September 2017 \n\nOxford BioMedica to Present at Cantor Fitzgerald Healthcare Conference 2017, New York\n \nOxford, UK - 25 September 2017: Oxford BioMedica plc (\"Oxford BioMedica\" or \"the Group\") (LSE:OXB), a leading gene and cell therapy group, today announces that Kyriacos Mitrophanous, Chief Scientific Officer, will be presenting at the Cantor Fitzgerald Healthcare Conference in New York on Wednesday 27 September at 16:35 Eastern Time. Stuart Paynter, Chief Financial Officer will also be attending the event.\n \n- Ends -\n \n \n\n\n\n\nFor further information, please contact:\n\n\n \n\n\n\n\n \nOxford BioMedica plc:\nJohn Dawson, Chief Executive Officer\nStuart Paynter, Chief Financial Officer\n \n\n\n \nTel: +44 (0)1865 783 000\n\n\n\n\nConsilium Strategic Communications\nMary-Jane Elliott/Matthew Neal/Philippa Gardner/Laura Thornton/Rosie Phillips\n \n\n\nTel: +44 (0)20 3709 5700\n\n\n\n\n \nNotes for editors\n \n \nAbout Oxford BioMedica\nOxford BioMedica (LSE:OXB) is a leading gene and cell therapy group focused on developing life changing treatments for serious diseases. Oxford BioMedica and its subsidiaries (the \"Group\") have built a sector leading lentiviral vector delivery platform (LentiVector®), which the Group leverages to develop in vivo and ex vivo products both in-house and with partners. The Group has created a valuable proprietary portfolio of gene and cell therapy product candidates in the areas of oncology, ophthalmology and CNS disorders. The Group has also entered into a number of partnerships, including with Novartis, Sanofi, GSK, Orchard Therapeutics and Immune Design, through which it has long-term economic interests in other potential gene and cell therapy products. Oxford BioMedica is based across several locations in Oxfordshire, UK and employs more than 280 people. Further information is available at www.oxfordbiomedica.co.uk.\n \n \n \n\nThis information is provided by RNSThe company news service from the London Stock Exchange END NRALIFSTAFIEFID\n ","length":3614,"tagName":"div"}]